|Day Low/High||156.32 / 160.66|
|52 Wk Low/High||125.84 / 197.00|
DUBLIN, Nov. 5, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Credit Suisse 27 th Annual Health Care Conference in Scottsdale,...
Let's check the charts and technical indicators for some guidance.
Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
The Dublin firm raised its outlook amid a delay in the launch of generic competition to its dry eye medication Restasis.
Global stocks attempted yet another rebound Tuesday, with reports of direction market intervention in China supporting prices in Asia and stronger-than-expected blue chip earnings putting European bourses on solid footing following a volatile session on Wall Street that saw a 900-point swing for the Dow Jones Industrial Average and a further worrying plunge in big-name tech companies.
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
- Q3 2018 GAAP Loss Per Share of $0.11; Non-GAAP Performance Net Income Per Share of $4.25 -
- Dividend to be Paid on December 14, 2018 -
Jim Cramer weighs in on Procter & Gamble, Six Flags, Western Digital, Allergan, Principal Financial Group.
Jim Cramer says somebody panicked, and their departure left behind a mess in the tech sector. But that spells a buying opportunity.
-- Actress Named as Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment* --
- The Manufacturing Institute's Career Skills Program Connects Veterans with Potential Manufacturing Jobs -
- Allergan Hosting Analyst Event at the 2018 AAO Annual Meeting Including Conference Call and Webcast on Friday, October 26, at 6:30 p.m. Central Time (7:30 p.m. Eastern Time) -
--One-year study continues to support positive safety and tolerability profile for ubrogepant--
DUBLIN and SAN FRANCISCO, Oct. 16, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines,...
DUBLIN, Oct. 11, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October...
DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it will present data from its gastroenterology portfolio at the American College of Gastroenterology Annual Scientific Meeting (ACG),...
- New programs will evaluate the safety and efficacy of brazikumab (an investigational drug) and the potential correlation between biomarkers and patient outcomes with brazikumab
DUBLIN, Oct. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting ® treatment received FDA clearance to treat the submandibular area.
Aegon's subsidiary Transamerica today announces an agreement that would resolve litigation challenging certain monthly deduction rate adjustments on universal life insurance policies in the United States.
Bigger, bolder JUVÉDERM® campaign seeks to make JUVÉDERM® a household name for consumers
DUBLIN, Oct. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018, prior to the open of U.
Straying from these names could land you in quicksand as the 4th quarter begins.
Allergan Foundation pledges $2,000,000 to support breast health research
- Application Seeks to Expand VRAYLAR Indication to Include the Treatment of Bipolar Depression -
Aegon expects a one-time benefit to capital generation of approximately USD 1 billion as a result of the merger of two legal entities.
The company and actor join forces to pay homage to those affected by Alzheimer's Disease
Aegon will repurchase 24,133,950 common shares to neutralize the dilutive effect of the 2018 interim stock dividend.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.